2026 Cosmobeauty Seoul

Nexvel Biotech Introduces Medical Technology-Based Cosmetic Brand ‘Du2LAB’ at COSMOBEAUTY SEOUL 2026 Integrated Manufacturing, R&D, Export, and Distribution System Strengthens Confidence in Functional Cosmeceutical Brand South Korean medical and bio company Nexvel Biotech is set to officially enter the beauty market through its cosmetic brand Du2LAB. The brand will make its domestic debut at COSMOBEAUTY SEOUL 2026, drawing industry attention as a functional cosmetic brand developed with medical-device-based technology. The global beauty industry is rapidly evolving beyond conventional skincare products toward the growing “cosmeceutical” sector, where consumers increasingly prioritize skin improvement, functionality, and safety. As purchasing standards shift from simple brand image to technological reliability, ingredient stability, and manufacturing credibility, companies with medical technology expertise are emerging as new leaders in the beauty industry. Against this backdrop, Nexvel Biotech has strengthened its competitiveness by establishing an integrated business structure that directly manages research and development (R&D), manufacturing, quality control, exports, and global distribution based on its patented medical device technologies. Industry experts note that companies capable of independently overseeing the entire process—from product development to global distribution—remain relatively rare in the Korean beauty industry. Building on its accumulated expertise in the medical aesthetics sector, Nexvel Biotech has expanded its business portfolio by launching Du2LAB, a functional cosmeceutical brand rooted in medical technology. The brand is being recognized for its differentiated competitiveness, as the company’s skin science-based technologies and quality management systems originally developed for medical devices have been applied to cosmetic product development. Industry analysts point out that modern consumers increasingly prefer products that deliver visible skin condition improvement and tangible user satisfaction rather than products that simply appear visually appealing. In particular, the medical cosmeceutical sector—driven by high-performance ingredients, advanced absorption technology, and product safety—is considered one of the fastest-growing segments within the global beauty market. Reflecting these market trends, Du2LAB plans to present a brand strategy that combines emotional brand experience with medically driven functionality. The products are reportedly formulated using Nexvel Biotech’s proprietary technologies, focusing on enhanced absorption efficiency, optimized active ingredient delivery, and product safety. In addition, Nexvel Biotech’s established global distribution network is regarded as another key factor supporting Du2LAB’s growth potential. Leveraging the international partnerships and export channels built through its medical device and medical aesthetics businesses, the company is expanding into the cosmetics sector while continuously strengthening connections with global buyers through participation in international exhibitions. Industry observers believe that Du2LAB’s credibility will be further enhanced by the fact that it is backed by a company operating its own manufacturing infrastructure and quality management systems. In the global beauty market, brands with in-house production capabilities are increasingly gaining competitive advantages as consumers place greater emphasis on quality stability and manufacturing transparency. A beauty industry expert commented, “The cosmetics industry has entered an era where emotional branding alone is no longer enough to remain competitive. Companies capable of combining technological expertise, manufacturing reliability, and global distribution competitiveness are expected to lead the market moving forward. Du2LAB represents a noteworthy example of a brand successfully integrating medical-based functionality with a premium branding strategy.” A representative from Nexvel Biotech stated, “COSMOBEAUTY SEOUL 2026 will serve as a meaningful opportunity to introduce Du2LAB to domestic consumers and buyers for the first time. We plan to continue strengthening the brand’s competitiveness through differentiated product development based on medical technology and expanded global market presence.” Meanwhile, COSMOBEAUTY SEOUL 2026 is recognized as one of Korea’s leading beauty industry exhibitions, attracting domestic and international beauty brands and buyers while serving as a key platform for showcasing the latest K-beauty technologies and global trends.  

2026.05.19

2026 Beauty Istanbul Exhibition

Nexvel Biotech Accelerates Global Expansion Evolving into a Total Medical Aesthetics Company Integrating Manufacturing, Distribution, and Cosmetics Based on Patented Medical Device Technology South Korean medical and bio company Nexvel Biotech is drawing industry attention as it officially begins expanding into global markets following its participation in BEAUTYISTANBUL 2026. Built upon patented medical device technologies, the company has established a business structure that directly manages the entire process from manufacturing to export and distribution. More recently, Nexvel Biotech has successfully launched a technology-based cosmetic brand, further strengthening its competitiveness in the medical aesthetics sector. Leveraging its accumulated expertise in medical devices and aesthetic medicine, Nexvel Biotech has developed an integrated business system that organically connects in-house research and development (R&D), manufacturing, and global distribution networks. Industry analysts note that the company differentiates itself by going beyond conventional OEM and ODM production, directly overseeing product planning, technology development, manufacturing, quality control, and overseas distribution. Industry experts point out that the global medical aesthetics market is increasingly shifting away from simple price competition toward a structure that prioritizes technological reliability, product safety, and brand competitiveness. In response to this trend, Nexvel Biotech has strengthened its global market competitiveness by enhancing product quality through its proprietary patented technologies. Through its participation in BEAUTYISTANBUL 2026, Nexvel Biotech actively introduced its medical aesthetics technologies and brand competitiveness to buyers across Europe, the Middle East, and Asia. During the exhibition, the company’s Aesthetic Medicines portfolio—including skin boosters and dermal fillers—received strong interest from overseas medical professionals and buyers, with positive evaluations focusing on product stability and differentiated formulation technologies. In particular, the company’s medical device-based technologies are now being applied to its recently launched cosmetic brand, generating positive market responses. Industry observers believe that this medically driven functional cosmetics approach aligns well with growing global consumer demand for products that combine efficacy, safety, and professional expertise. The global beauty market has recently seen rapid growth in the “cosmeceutical” sector, where consumers increasingly seek both skin improvement benefits and medical-grade reliability, further increasing the market influence of companies with medical technology expertise. Keeping pace with these trends, Nexvel Biotech is expanding the R&D capabilities and quality management systems established in the medical device sector into the cosmetics field. Industry insiders note that global markets are increasingly placing greater trust in companies that directly operate their own manufacturing infrastructure and quality control systems. They also emphasize that medical technology-based companies entering the cosmetics industry can gain strong advantages in both product reliability and premium brand positioning. At the same time, Nexvel Biotech is accelerating the expansion of its global distribution network. Beginning with the Istanbul exhibition, the company plans to continue participating in major international exhibitions across Europe, the Middle East, and Asia to strengthen overseas partnerships and export channels. Active consultations with buyers and distributors from various countries are already underway, and discussions regarding exclusive distribution agreements and long-term supply partnerships are reportedly progressing in several regions. A representative from Nexvel Biotech stated, “Based on our patented technologies, in-house production infrastructure, and global distribution capabilities, we plan to further strengthen our competitiveness in the medical aesthetics market. We aim to build sustainable growth in global markets by expanding not only our medical device business but also our technology-driven cosmetics sector.” Meanwhile, the global medical aesthetics and cosmeceutical markets continue to experience steady growth driven by increasing demand for skin health and anti-aging solutions. Industry experts expect Korean companies that successfully secure technological expertise, manufacturing competitiveness, and global distribution capabilities simultaneously to stand out even more prominently in overseas markets in the future.        

2026.05.07

[Nexvel Biotech] Accelerates Global Expansion at BEAUTYISTANBUL 2026

Nexvel Biotech Accelerates Global Expansion at BEAUTYISTANBUL 2026Advanced HA-Based Aesthetic Solutions Draw Attention from Global Buyers and Medical Professionals South Korean medical aesthetic company Nexvel Biotech is accelerating its expansion into overseas markets after participating in BEAUTYISTANBUL 2026, one of the largest beauty exhibitions serving as a strategic hub connecting Europe, Asia, and the Middle East. Recognized as a key international exhibition linking Europe, the Middle East, and CIS countries, BEAUTYISTANBUL brings together global beauty and aesthetic brands, medical professionals, distributors, and buyers. In recent years, the exhibition has also emerged as a major platform for competition in the medical aesthetics sector, particularly amid growing global demand for skin boosters and dermal fillers. At this year’s exhibition, Nexvel Biotech showcased its core Aesthetic Medicines portfolio, including Dual HA Skin Booster, Aeshilo, CE-certified Roseeplla Filler, and the Amethea Skin Booster series. According to industry sources, the company attracted strong interest from overseas medical professionals and distributors, particularly regarding product stability, differentiated formulations, and clinical suitability. Industry experts especially highlighted the company’s Dual HA-based skin booster technology. By combining high- and low-molecular-weight hyaluronic acid (HA), the formulation is designed to simultaneously enhance long-lasting hydration and skin elasticity. As the global medical aesthetics market increasingly shifts beyond simple volumizing procedures toward “skin quality” enhancement, this multifunctional approach is being viewed as a strong competitive advantage. The CE-certified Roseeplla Filler also drew attention for its potential competitiveness in the European market. CE certification is recognized as a key indicator that a product meets the safety and quality standards required for entry into Europe, making it an essential factor in global market expansion. Industry officials noted that international markets are increasingly prioritizing product safety and clinical reliability over price competitiveness alone, emphasizing the growing importance of advanced technology and global certifications for Korean aesthetic manufacturers. During the exhibition, Nexvel Biotech also engaged in active consultations with buyers from Europe, the Middle East, and Southeast Asia. Discussions regarding product supply partnerships and distribution agreements were particularly active in countries experiencing rapid growth in premium clinic-centered aesthetic markets, raising expectations for future expansion of the company’s global distributor network. A representative from Nexvel Biotech stated, “Through our participation in BEAUTYISTANBUL 2026, we were able to effectively introduce our technological capabilities and product competitiveness to the global market. We will continue strengthening our presence in the international medical aesthetics industry through ongoing R&D investment and the expansion of global certifications.” Meanwhile, the global medical aesthetics market continues to experience steady growth driven by rising demand for skin rejuvenation and anti-aging treatments. Skin boosters and dermal fillers are expected to remain among the key categories leading future market expansion, while industry attention is increasingly focused on how Korean companies’ technology-driven premium strategies will perform on the global stage.

2026.05.07